Retrospective analysis of extra-gastrointestinal stromal tumorsopen access
- Authors
- Yi, Jun Ho; Park, Byeong-Bae; Kang, Jung Hun; Hwang, In Gyu; Shin, Dong Bok; Sym, Sun Jin; Ahn, Hee Kyung; Lee, Soon Il; Lim, Do Hyoung; Park, Keon Woo; Won, Young-Woong; Lim, Sung Hee; Park, Se Hoon
- Issue Date
- Feb-2015
- Publisher
- BAISHIDENG PUBLISHING GROUP INC
- Keywords
- Gastrointestinal stromal tumor; Survival; Imatinib; Risk factor; Prognostic factor
- Citation
- WORLD JOURNAL OF GASTROENTEROLOGY, v.21, no.6, pp.1845 - 1850
- Indexed
- SCIE
SCOPUS
- Journal Title
- WORLD JOURNAL OF GASTROENTEROLOGY
- Volume
- 21
- Number
- 6
- Start Page
- 1845
- End Page
- 1850
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/158007
- DOI
- 10.3748/wjg.v21.i6.1845
- ISSN
- 1007-9327
- Abstract
- AIM: To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors (EGISTs) in South Korea. METHODS: A total of 51 patients with an EGIST were identified. The clinicopathologic features, including sex, age, location, tumor size, histology, mitotic rate, immunohistochemical features, genetic status and survival data, were analyzed. RESULTS: The median age was 55 years (range: 29-80 years), and male: female ratio was 1: 1.04. The most common site was in the mesentery (n = 15) followed by the retroperitoneum (n = 13) and omentum (n = 8). The median tumor size was 9.0 cm (range: 2.6-30.0 cm) and the median mitotic rate was 5.0/50HPF. (1/50 - 185/50). KIT was analyzed in 16, which revealed 10 cases with wild-type KIT and 6 cases with an exon 11 mutation. Among 51 patients, 31 patients had undergone surgery, and 10 had unresectable disease and had taken palliative imatinib, which resulted in 22.7 mo of progression-free survival. Of the patients who had undergone surgery, 18 did not take adjuvant imatinib, and 8 of these were categorized as "high risk" according to the risk criteria. However, the relapse-free survival was not different (P = 0.157) between two groups. CONCLUSION: Because the biologic behaviors of GISTs differ according to the location of the tumor, a more stratified strategy is required for managing EGISTs including incorporation of molecular features.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/158007)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.